pSivida to Present at the Ladenburg Thalmann 2017
Post# of 301275
WATERTOWN, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker, President and Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 10:30 am (ET) at the Sofitel Hotel in New York, NY.
A live audio and/or webcast and subsequent archived replay of pSivida’s presentations may be accessed via the Investors section of the Company’s website under “Resources - Events & Presentations” at www.psivida.com . The replay will be available for 90 days after the event.
About pSivida Corp .
pSivida Corp. ( www.psivida.com ), headquartered in Watertown, MA, is a leader in the development of sustained release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN ® , a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold directly in the U.S. and three EU countries. Retisert ® , an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert™ micro-insert for posterior segment uveitis, is being independently developed. Two pivotal Phase 3 studies with Durasert achieved their primary efficacy endpoint of prevention of recurrence of uveitis at six months of follow-up with statistical significance, and the Company plans to file an NDA by late December 2017/early January 2018. pSivida's pre-clinical development program is focused on using its core platform technology Durasert™ to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida, please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.
Contact:
EVC Group Michael Polyviou/Doug Sherk – Investors mpolyviou@evcgroup.com ; dsherk@evcgroup.com 212.850.6020; 646-445-4800
Thomas Gibson – Media tom@tomgibsoncommunications.com 201-476-0322
(0)
(0)